CADL
Candel Therapeutics Inc (CADL)
Healthcare • NASDAQ • $8.35+7.19%
- Symbol
- CADL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $8.35
- Daily Change
- +7.19%
- Market Cap
- $611.81M
- Trailing P/E
- N/A
- Forward P/E
- -13.05
- 52W High
- $8.36
- 52W Low
- $4.35
- Analyst Target
- $18.88
- Dividend Yield
- N/A
- Beta
- -0.58
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Thera…
Company websiteResearch CADL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.